1. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs.
- Author
-
Zeng, Baitao, Zhou, Miaojin, Liu, Bo, Shen, Fei, Xiao, Rou, Su, Jiasun, Hu, Zhiqing, Zhang, Yiti, Gu, Ao, Wu, Lingqian, Liu, Xionghao, and Liang, Desheng
- Subjects
- *
DUCHENNE muscular dystrophy , *INDUCED pluripotent stem cells , *DYSTROPHIN genes , *RECOMBINANT DNA , *LOCUS (Genetics) , *GENETIC mutation , *RIBOSOMAL DNA - Abstract
Duchenne muscular dystrophy (DMD), the most common lethal muscular disorder, affects 1 in 5000 male births. It is caused by mutations in the X-linked dystrophin gene (DMD), and there is no effective treatment currently. Gene addition is a promising strategy owing to its universality for patients with all gene mutations types. In this study, we describe a site-specific gene addition strategy in induced pluripotent stem cells (iPSCs) derived from a DMD patient with exon 50 deletion. By using transcription activator-like effector nickases (TALENickases), the mini-dystrophin cassette was precisely targeted at the ribosomal RNA gene (rDNA) locus via homologous recombination with high targeting efficiency. The targeted clone retained the main pluripotent properties and was differentiated into cardiomyocytes. Significantly, the dystrophin expression and membrane localization were restored in the genetic corrected iPSCs and their derived cardiomyocytes. More importantly, the enhanced spontaneous contraction was observed in modified cardiomyocytes. These results provide a proof of principle for an efficient targeted gene addition for DMD gene therapy and represents a significant step toward precisely therapeutic for DMD. • Site-specific integrated mini-dystrophin into rDNA locus in DMD-iPSCs. • Dystrophin expression and localization were restored in targeted iPSCs and iCMs. • The enhanced spontaneous contraction was observed in the targeted iCMs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF